TY - STD TI - Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018. https://doi.org/10.3322/caac.21492. ID - ref1 ER - TY - STD TI - Amini A, Byers LA, Welsh JW, Komaki RU. Progress in the management of limited-stage small cell lung cancer. Cancer. 2014;120(6). https://doi.org/10.1002/cncr.28505. ID - ref2 ER - TY - STD TI - Mead GM, Arnold AM, Green JA, Williams CJ, Whitehouse JM. SMALL-CELL LUNG CANCER[J]. Cancer Chemother Pharmacol. 1980;315(8162):252. https://doi.org/10.1016/S0140-6736(80)90733-3. ID - ref3 ER - TY - JOUR AU - Powell, H. A. AU - Tata, L. J. AU - Baldwin, D. R. AU - Potter, V. A. AU - Stanley, R. A. AU - Khakwani, A. PY - 2014 DA - 2014// TI - Treatment decisions and survival for people with small-cell lung cancer JO - Br J Cancer VL - 110 UR - https://doi.org/10.1038/bjc.2013.812 DO - 10.1038/bjc.2013.812 ID - Powell2014 ER - TY - JOUR AU - Huang, R. S. P. AU - Holmes, B. F. AU - Powell, C. AU - Marati, R. V. AU - Tyree, D. AU - Admire, B. PY - 2019 DA - 2019// TI - Delta-like protein 3 prevalence in small cell lung cancer and DLL3 (SP347) assay characteristics JO - Arch Pathol Lab Med VL - 143 UR - https://doi.org/10.5858/arpa.2018-0497-OA DO - 10.5858/arpa.2018-0497-OA ID - Huang2019 ER - TY - JOUR AU - Morgensztern, D. AU - Besse, B. AU - Greillier, L. AU - Santana-Davila, R. AU - Ready, N. AU - Hann, C. L. PY - 2019 DA - 2019// TI - Efficacy and safety of rovalpituzumab tesirine in third-line and beyond patients with DLL3-expressing, relapsed/refractory small-cell lung cancer: results from the phase II TRINITY study JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-19-1133 DO - 10.1158/1078-0432.CCR-19-1133 ID - Morgensztern2019 ER - TY - JOUR AU - Isobe, Y. AU - Sato, K. AU - Nishinaga, Y. AU - Takahashi, K. AU - Taki, S. AU - Yasui, H. PY - 2020 DA - 2020// TI - Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer JO - EBioMedicine VL - 52 UR - https://doi.org/10.1016/j.ebiom.2020.102632 DO - 10.1016/j.ebiom.2020.102632 ID - Isobe2020 ER - TY - JOUR AU - Rossi, A. PY - 2017 DA - 2017// TI - Rovalpituzumab tesirine and DLL3: a new challenge for small-cell lung cancer JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/s1470-2045(16)30575-7 DO - 10.1016/s1470-2045(16)30575-7 ID - Rossi2017 ER - TY - JOUR AU - Rudin, C. M. AU - Pietanza, M. C. AU - Bauer, T. M. AU - Ready, N. AU - Morgensztern, D. AU - Glisson, B. S. PY - 2017 DA - 2017// TI - Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study JO - Lancet Oncol VL - 18 UR - https://doi.org/10.1016/s1470-2045(16)30565-4 DO - 10.1016/s1470-2045(16)30565-4 ID - Rudin2017 ER - TY - JOUR AU - Fu, X. AU - Tian, T. AU - Liu, M. AU - Ruan, Z. AU - Liang, X. AU - Nan, K. PY - 2019 DA - 2019// TI - The expression and prognostic roles of PD-L1, PAPR1 and DLL3 in small cell lung cancer JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.08.2267 DO - 10.1016/j.jtho.2019.08.2267 ID - Fu2019 ER - TY - JOUR AU - Lim, S. AU - Hong, M. AU - Kim, S. P. AU - Chung, S. H. PY - 2019 DA - 2019// TI - P2. 12-18 Prevalence of DLL3 Expression and its prognostic role in extensive stage small cell lung cancer JO - J Thorac Oncol VL - 14 UR - https://doi.org/10.1016/j.jtho.2019.08.1763 DO - 10.1016/j.jtho.2019.08.1763 ID - Lim2019 ER - TY - JOUR AU - Poirier, J. T. PY - 2020 DA - 2020// TI - Targeting DLL3 in small-cell lung cancer with novel modalities JO - J Thorac Oncol VL - 15 UR - https://doi.org/10.1016/j.jtho.2019.12.024 DO - 10.1016/j.jtho.2019.12.024 ID - Poirier2020 ER - TY - JOUR AU - Liberati, A. AU - Altman, D. G. AU - Tetzlaff, J. AU - Mulrow, C. AU - Gøtzsche, P. C. AU - Ioannidis, J. P. A. PY - 2009 DA - 2009// TI - The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration JO - J Clin Epidemiol VL - 62 UR - https://doi.org/10.1016/j.jclinepi.2009.06.006 DO - 10.1016/j.jclinepi.2009.06.006 ID - Liberati2009 ER - TY - JOUR AU - Tierney, J. F. AU - Stewart, L. A. AU - Ghersi, D. AU - Burdett, S. AU - Sydes, M. R. PY - 2007 DA - 2007// TI - Practical methods for incorporating summary time-to-event data into meta-analysis JO - Trials VL - 8 UR - https://doi.org/10.1186/1745-6215-8-16 DO - 10.1186/1745-6215-8-16 ID - Tierney2007 ER - TY - JOUR AU - Jill, A. AU - Hayden, D. AU - Windt, D. A. AU - Cartwright, J. L. AU - Côté, P. AU - Bombardier, C. PY - 2013 DA - 2013// TI - Assessing bias in studies of prognostic factors JO - Ann Int Med VL - 158 UR - https://doi.org/10.7326/0003-4819-158-4-201302190-00009 DO - 10.7326/0003-4819-158-4-201302190-00009 ID - Jill2013 ER - TY - JOUR AU - Higgins, T. J. P. PY - 2003 DA - 2003// TI - Measuring inconsistency in meta-analyses JO - BMJ VL - 327 UR - https://doi.org/10.1136/bmj.327.7414.557 DO - 10.1136/bmj.327.7414.557 ID - Higgins2003 ER - TY - JOUR AU - Dersimonian, R. AU - Nan, L. PY - 1986 DA - 1986// TI - Meta-analysis in clinical trials JO - Control Clin Trials VL - 7 UR - https://doi.org/10.1016/0197-2456(86)90046-2 DO - 10.1016/0197-2456(86)90046-2 ID - Dersimonian1986 ER - TY - JOUR AU - Mengersen, K. L. AU - Tweedie, R. L. AU - Biggerstaff, B. PY - 2008 DA - 2008// TI - The impact of method choice on meta-analysis JO - Aust N Z J Stat VL - 37 UR - https://doi.org/10.1111/j.1467-842X.1995.tb00869.x DO - 10.1111/j.1467-842X.1995.tb00869.x ID - Mengersen2008 ER - TY - JOUR AU - Ahmed, I. AU - Sutton, A. J. AU - Riley, R. D. PY - 2012 DA - 2012// TI - Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey JO - BMJ VL - 344 UR - https://doi.org/10.1136/bmj.d776 DO - 10.1136/bmj.d776 ID - Ahmed2012 ER - TY - JOUR AU - Yan, L. X. AU - Liu, Y. H. AU - Li, Z. AU - Luo, D. L. AU - Li, Y. F. AU - Yan, J. H. PY - 2019 DA - 2019// TI - Prognostic value of delta-like protein 3 combined with thyroid transcription factor-1 in small-cell lung cancer JO - Oncol Lett VL - 18 UR - https://doi.org/10.3892/ol.2019.10538 DO - 10.3892/ol.2019.10538 ID - Yan2019 ER - TY - JOUR AU - Xie, H. AU - Boland, J. M. AU - Maleszewski, J. J. AU - Aubry, M. C. AU - Yi, E. S. AU - Jenkins, S. M. PY - 2019 DA - 2019// TI - Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors JO - Lung Cancer VL - 135 UR - https://doi.org/10.1016/j.lungcan.2019.07.016 DO - 10.1016/j.lungcan.2019.07.016 ID - Xie2019 ER - TY - JOUR AU - Tanaka, K. AU - Isse, K. AU - Fujihira, T. AU - Takenoyama, M. AU - Saunders, L. AU - Bheddah, S. PY - 2018 DA - 2018// TI - Prevalence of delta-like protein 3 expression in patients with small cell lung cancer JO - Lung Cancer VL - 115 UR - https://doi.org/10.1016/j.lungcan.2017.11.018 DO - 10.1016/j.lungcan.2017.11.018 ID - Tanaka2018 ER - TY - JOUR AU - Regzedmaa, O. AU - Li, Y. AU - Li, Y. AU - Zhang, H. AU - Wang, J. AU - Gong, H. PY - 2019 DA - 2019// TI - Prevalence of DLL3, CTLA-4 and MSTN expression in patients with small cell lung cancer JO - Onco Targets Ther VL - 12 UR - https://doi.org/10.2147/OTT.S216362 DO - 10.2147/OTT.S216362 ID - Regzedmaa2019 ER - TY - JOUR AU - Huang, J. AU - Cao, D. AU - Sha, J. AU - Zhu, X. AU - Han, S. PY - 2019 DA - 2019// TI - DLL3 is regulated by LIN28B and miR-518d-5p and regulates cell proliferation, migration and chemotherapy response in advanced small cell lung cancer JO - Biochem Biophys Res Commun VL - 514 UR - https://doi.org/10.1016/j.bbrc.2019.04.130 DO - 10.1016/j.bbrc.2019.04.130 ID - Huang2019 ER - TY - JOUR AU - Furuta, M. AU - Sakakibara-Konishi, J. AU - Kikuchi, H. AU - Yokouchi, H. AU - Nishihara, H. AU - Minemura, H. PY - 2019 DA - 2019// TI - Analysis of DLL3 and ASCL1 in surgically resected small cell lung cancer (HOT1702) JO - Oncologist VL - 24 UR - https://doi.org/10.1634/theoncologist.2018-0676 DO - 10.1634/theoncologist.2018-0676 ID - Furuta2019 ER - TY - STD TI - Koshkin VS, Elson P, Magi-Galluzzi C, McKenney J, Smith KS, Shadrach B, et al. Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC). J Clin Oncol. 2017;35(6):382. ID - ref26 ER - TY - JOUR AU - Juan AU - Wang AU - Kaishuo AU - Zhang AU - Zi AU - Liu PY - 2018 DA - 2018// TI - Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer: a retrospective study JO - Medicine (Baltimore) VL - 97 UR - https://doi.org/10.1097/MD.0000000000013442 DO - 10.1097/MD.0000000000013442 ID - Juan2018 ER - TY - JOUR AU - Matos, L. L. D. AU - Stabenow, E. AU - Tavares, M. R. AU - Ferraz, A. R. AU - Capelozzi, V. L. AU - Pinhal, M. A. D. S. PY - 2006 DA - 2006// TI - Immunohistochemistry quantification by a digital computer-assisted method compared to semiquantitative analysis JO - Clinics VL - 61 UR - https://doi.org/10.1590/S1807-59322006000500008 DO - 10.1590/S1807-59322006000500008 ID - Matos2006 ER - TY - STD TI - Hann CL, Morgensztern D, Dowlati A, Burns TF, Jotte RM, Pennell NA, et al. A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer. J Clin Oncol. 2017;35. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS2598. ID - ref29 ER - TY - STD TI - Furuta M, Sakakibara JK, Shoji T, Takashima Y, Kikuchi H, Kikuchi E, et al. DLL3 regulates migration and invasion of small cell lung cancer. Cancer Res. 2018;78(13). https://doi.org/10.1158/1538-7445.Am2018-3158. ID - ref30 ER - TY - JOUR AU - Sriuranpong, V. AU - Borges, M. W. AU - Ravi, R. K. AU - Arnold, D. R. AU - Nelkin, B. D. AU - Baylin, S. B. PY - 2001 DA - 2001// TI - Notch signaling induces cell cycle arrest in small cell lung cancer cells JO - Cancer Res VL - 61 UR - https://doi.org/10.1097/00002820-200104000-00012 DO - 10.1097/00002820-200104000-00012 ID - Sriuranpong2001 ER - TY - JOUR AU - Deng, S. M. AU - Yan, X. C. AU - Liang, L. AU - Wang, L. AU - Liu, Y. AU - Duan, J. L. PY - 2017 DA - 2017// TI - The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice JO - Biochem Biophys Res Commun VL - 483 UR - https://doi.org/10.1016/j.bbrc.2016.12.117 DO - 10.1016/j.bbrc.2016.12.117 ID - Deng2017 ER - TY - JOUR AU - Komarnitsky, P. AU - Lee, H. AU - Shah, M. AU - Wong, S. AU - Gulbranson, S. AU - Dziubinski, J. PY - 2017 DA - 2017// TI - Rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following 1st line chemotherapy JO - J Thorac Oncol VL - 12 UR - https://doi.org/10.1016/j.jtho.2017.09.865 DO - 10.1016/j.jtho.2017.09.865 ID - Komarnitsky2017 ER - TY - JOUR AU - Udagawa, H. AU - Akamatsu, H. AU - Tanaka, K. AU - Takeda, M. AU - Kanda, S. AU - Kirita, K. PY - 2019 DA - 2019// TI - Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer JO - Lung Cancer VL - 135 UR - https://doi.org/10.1016/j.lungcan.2019.07.025 DO - 10.1016/j.lungcan.2019.07.025 ID - Udagawa2019 ER - TY - JOUR AU - Komarnitsky, P. AU - Lee, H. J. AU - Shah, M. AU - Wong, S. AU - Gulbranson, S. AU - Dziubinski, J. PY - 2017 DA - 2017// TI - A phase 3 trial of rovalpituzumab tesirine vs topotecan in patients with advanced small cell lung cancer following frontline platinumbased chemotherapy JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx386.009 DO - 10.1093/annonc/mdx386.009 ID - Komarnitsky2017 ER - TY - JOUR AU - Odashiro, P. AU - Tomarchio, G. AU - Gagne, A. AU - Orain, M. AU - Desmeules, P. AU - Joubert, P. PY - 2020 DA - 2020// TI - DLL3 expression in small cell lung carcinomas (SCLC) JO - Mod Pathol VL - 33 ID - Odashiro2020 ER -